Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis
Journal of Antimicrobial Chemotherapy · 04.11.2025 · 80 (11) · 3150-3159
DOI: 10.1093/jac/dkaf355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 24.09.2025. Verfasst von Christopher A Darlow und 10 weiteren Autor:innen. Beteiligte Einrichtung: Antimicrobial Therapeutics and Pharmacodynamics, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Triazoles, Antifungal Agents, Invasive Pulmonary Aspergillosis, Aspergillus fumigatus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MRC, Wellcome Trust, National Institute for Healthcare Research.
Abstract (Originalsprache)
Background
Olorofim is a new antifungal agent with a novel mechanism of action with in vitro activity against Aspergillus fumigatus and other clinically important moulds. As antifungal combinations are of interest to extend the spectrum of coverage and improve antifungal activity, we investigated the pharmacodynamics of olorofim in combination with posaconazole.
Methods
Using galactomannan as a pharmacodynamic endpoint, olorofim and posaconazole were assessed alone and in combination in a neutropenic murine model of pulmonary aspergillosis using wild-type and triazole-resistant strains of A. fumigatus. Pharmacokinetic and pharmacodynamic data were fitted to a pharmacodynamic interaction model. Monte Carlo simulations of human-like regimens of both agents alone and in combination were performed to extrapolate to clinical settings.
Results
With the triazole-susceptible isolate, both monotherapy arms suppressed galactomannan, but suppression with the combination was less than expected from the monotherapy arms. With the triazole-resistant isolate, monotherapy produced galactomannan suppression with olorofim but not posaconazole; the combination arm produced less suppression than olorofim alone. The interaction model revealed antagonistic pharmacodynamic interaction parameter values. Extrapolations to human pharmacokinetics predicted that combination therapy would still have a net beneficial effect in A. fumigatus infections, albeit with reduced efficacy in infections with triazole-resistant isolates.
Conclusions
Posaconazole reduces the effect of olorofim in vivo. A combination of olorofim and a mould-active triazole is likely efficacious in wild-type infections but may be suboptimal in triazole resistance infections where there is minimal contribution of the mould-active triazole to antifungal activity and the triazole antagonises olorofim to produce a submaximal effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Antimicrobial Therapeutics and Pharmacodynamics, University of Liverpool, Liverpool, UK.
- Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
ORCID-Profile: Christopher A Darlow, Shampa Das
Förderung
- MRC
- Wellcome Trust
- National Institute for Healthcare Research
Zitieren
APA
Darlow, C. A., Farrington, N., Märtson, A. G., Johnson, A., McEntee, L., Horner, I., Stevenson, A., Jimenez-Valverde, A., Unsworth, J., Das, S., & Hope, W. (2025). Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy, 80(11), 3150-3159. https://doi.org/10.1093/jac/dkaf355
Vancouver
Darlow CA, Farrington N, Märtson AG, Johnson A, McEntee L, Horner I, et al. Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy. 2025;80(11):3150-3159. doi:10.1093/jac/dkaf355
BibTeX
@article{Darlow2025,
author = {Darlow, Christopher A and Farrington, Nicola and Märtson, Anne-Grete and Johnson, Adam and McEntee, Laura and Horner, Iona and Stevenson, Adam and Jimenez-Valverde, Ana and Unsworth, Jennifer and Das, Shampa and Hope, William},
title = {Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {11},
pages = {3150--3159},
doi = {10.1093/jac/dkaf355}
}
EUVIMED